| Author |
|
Replicant
Moderator
Joined: 01 Nov 2006
Posts: 744
|
 Posted: Wed Sep 02, 2009 4:09 pm Post subject: PCA3 |
 |
|
You guys should be proud of me. I was about to reply to another thread where PCA3 came up, but I caught myself. So here's a new topic.
Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
SAN DIEGO, Aug. 27 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company has begun a clinical trial intended to secure U.S. regulatory approval of its PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.
"Based on the results of our extensive clinical research studies and our European commercial experience, we believe that our PROGENSA PCA3 assay can help predict the risk of a positive follow-up biopsy, thereby improving patient care," said Eric Lai, PhD, Gen-Probe's senior vice president of research and development. "In addition, this is an important step forward in our efforts to maximize the economic value of our oncology strategy."
Complete news release: http://www.gen-probe.com/news/PressReleaseText.asp?compid=135117&releaseID=1325224
Here's a link to a Google news search on PCA3:
http://news.google.com/news/search?pz=1&ned=us&hl=en&q=pca3
_________________
Replicant
Dx Feb 2006, PSA 9 @age 43
RRP Apr 2006 - Gleason 3+4, T2c, NXMX, pos margins
PSA 5/06 <0.1, 8/06 0.2, 12/06 0.6, 1/07 0.7.
Salvage radiation (IMRT) total dose 70.2 Gy, Jan-Mar 2007@ age 44
PSA 6/07 0.1, 9/07 (and thereafter) <0.1
http://pcabefore50.blogspot.com |
|
| Back to top |
|
|
|
johnT
Senior User
Joined: 27 Apr 2009
Posts: 176
|
| Posted: Wed Sep 02, 2009 4:25 pm Post subject: Re: PCA3 |
|
|
Is this the same PCA3 test that is currently being given or a new varient of it? If so how does it differ from the current test?
JohnT
_________________
psa at diagnosis 40 in nov-08
gleason 6 and 7
Treatment choice seeds and IMRT |
|
| Back to top |
|
|
|
Replicant
Moderator
Joined: 01 Nov 2006
Posts: 744
|
| Posted: Wed Sep 02, 2009 4:43 pm Post subject: same one |
|
|
I think it's the same one, from what the press release says:
"Gen-Probe's PROGENSA(R) PCA3 assay, which has been CE-marked for sale in the European Union, is the first urine-based molecular diagnostic assay for prostate cancer. The test has not been approved for marketing in the United States.
Gen-Probe acquired exclusive worldwide diagnostic rights to the PCA3 gene from DiagnoCure (TSX: CUR) in November of 2003."
According to the company:
"No PCA3 test has been cleared or approved by the U.S. Food and Drug Administration (FDA). However, several laboratories in the U.S. are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing."
http://www.pca3.org/public
_________________
Replicant
Dx Feb 2006, PSA 9 @age 43
RRP Apr 2006 - Gleason 3+4, T2c, NXMX, pos margins
PSA 5/06 <0.1, 8/06 0.2, 12/06 0.6, 1/07 0.7.
Salvage radiation (IMRT) total dose 70.2 Gy, Jan-Mar 2007@ age 44
PSA 6/07 0.1, 9/07 (and thereafter) <0.1
http://pcabefore50.blogspot.com |
|
| Back to top |
|
|
|
|
Search 
Email Digests
Register to post
Profile 
Check private messages 
Log in
What is this ?
We subscribe to the HONcode principles. Verify here. All content and posts are copyright.
